Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Justin Walsh Analyst Performance

Analyst at B. Riley Financial

Justin Walsh is a stock analyst at B. Riley Financial in the medical sector, covering 11 publicly traded companies. Over the past year, Justin Walsh has issued 10 stock ratings, including strong buy, buy, and hold recommendations. While full access to Justin Walsh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Walsh's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 1 Years
Buy Recommendations
71.43% 10 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy7.1%1 ratings
Buy64.3%9 ratings
Hold28.6%4 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Justin Walsh at B. Riley Financial, the majority (64.3%) have been Buy recommendations, followed by 28.6% Hold and 7.1% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
81.8% of companies on NASDAQ
9 companies
NYSE
9.1% of companies on NYSE
1 company
NYSEAMERICAN
9.1% of companies on NYSEAMERICAN
1 company

Justin Walsh, an analyst at B. Riley Financial, currently covers 11 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
11 companies
100.0%

Justin Walsh of B. Riley Financial specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
54.5%
MEDICAL SERVICES
1 company
9.1%
MED PRODUCTS
1 company
9.1%
BIOTECHNOLOGY
1 company
9.1%
MED - OUTP/HM CRE
1 company
9.1%
MED - DRUGS
1 company
9.1%

Justin Walsh's Ratings History at B. Riley Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/2/2026Lower Price Target$22.47$44.00Buy
NeuroOne Medical Technologies Corporation stock logo
NMTC
NeuroOne Medical Technologies
3/2/2026Initiated Coverage$4.02$9.00Buy
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2/27/2026Downgrade$75.43Hold
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
12/23/2025Initiated Coverage$13.30$61.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
12/23/2025Initiated Coverage$4.30$16.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
9/18/2025Initiated Coverage$44.03$83.00Buy
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
9/16/2025Lower Price Target$51.49$84.00Buy
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
8/5/2025Downgrade$8.52Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
6/23/2025Lower Price Target$80.26$109.00Buy
VolitionRX Limited stock logo
VNRX
VolitionRX
6/10/2025Upgrade$11.13$60.00Strong-Buy
Clene Inc. stock logo
CLNN
Clene
4/23/2025Initiated Coverage$2.98$30.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
4/2/2025Reiterated Rating$33.43Hold
BioLineRx Ltd. stock logo
BLRX
BioLineRx
4/2/2025Reiterated Rating$2.92Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3/21/2025Lower Price Target$98.85$122.00Buy